PDI seeks new CEO following Marquad retirement

Share this article:
Contract sales firm PDI has announced the retirement of its CEO Michael Marquard.

In a statement issued by the company today, PDI said it will immediately begin a search for a new CEO. While the search is under way, John Dugan, chairman of the board, former CEO and founder of the company, will play a more active role in overseeing operations, PDI said. Jeffrey Smith, PDI's EVP, finance and CFO, has been named interim CEO.

Marquad joined PDI as CEO in May 2006. Prior to joining PDI he was president of Mylan Bertek Pharmaceuticals, VP of Mylan Laboratories and SVP of US sales for Wyeth, where he led a 5,000-person US sales organization. Marquard began his career as a medical sales rep with Lederle Laboratories.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.